SCHEMBL822382

SCHEMBL822382

Nc1nc(NCCc2ccccc2)c2nc[nH]c2n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 2/20 0.67
APP P05067 1/20 0.57
MAPK1 P28482 1/20 0.50
HTT P42858 1/20 0.50
TAAR1 Q96RJ0 1/20 0.50
EGFR P00533 1/20 0.49
KDR P35968 1/20 0.49
CDK1 P06493 2/20 0.49
TLR8 Q9NR97 6/20 0.46
TLR7 Q9NYK1 6/20 0.46
SLC29A1 Q99808 1/20 0.44
IP6K1 Q92551 1/20 0.44
HSD17B10 Q99714 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
TSHR P16473 2/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL822377 0.86 CDK1 (0.65) NUDT1APPMAPK1EGFRKDR
SCHEMBL9609211 0.82 MAPK1 (0.64) NUDT1APPMAPK1HTTTAAR1
SCHEMBL5695061 0.81 CTSL (0.53) NUDT1MAPK1HTTTAAR1IP6K1
SCHEMBL17933838 0.80 NUDT1 (1.00) NUDT1APPMAPK1HTTTAAR1
SCHEMBL10838740 0.80 NUDT1 (0.41) NUDT1APPCDK1TLR8TLR7
SCHEMBL6950876 0.79 MPO (0.56) NUDT1APPCDK1HSD17B10CYP2D6
SCHEMBL8826353 0.79 CHUK (0.50) NUDT1MAPK1EGFRCDK1TLR8
SCHEMBL8826182 0.79 APP (0.47) NUDT1APPHTTTLR8TLR7
SCHEMBL9792866 0.78 APP (0.57) NUDT1APPMAPK1HTTTAAR1
SCHEMBL6948069 0.77 MPO (0.47) NUDT1CDK1TLR8TLR7HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
EP-4115882-A1 COMPOUNDS FOR IMPROVING MRNA SPLICING The General Hospital Corporation (US) 2023-01-11 EP disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed
WO-2016115434-A1 COMPOUNDS FOR IMPROVING MRNA SPLICING THE GENERAL HOSPITAL CORPORATION (US) 2016-07-21 WO disclosed
US-9151883-B2 Cellulose acylate film, retardation film, polarizer and liquid-crystal display device FUJIFILM CORPORATION (JP) 2015-10-06 US disclosed
US-8158220-B2 Cellulose acylate film, retardation film, polarizer and liquid crystal display device FUJIFILM CORPORATION (JP) 2012-04-17 US disclosed
US-8158220-B2 Cellulose acylate film, retardation film, polarizer and liquid crystal display device FUJIFILM CORPORATION (JP) 2012-04-17 US disclosed
US-20120018685-A1 Optical film, retardation film, polarizing plate, and liquid crystal display device FUJIFILM CORPORATION (JP) 2012-01-26 US disclosed
US-20120018685-A1 Optical film, retardation film, polarizing plate, and liquid crystal display device FUJIFILM CORPORATION (JP) 2012-01-26 US disclosed
US-20110262661-A1 Optical performance humidity dependency improving agent for cellulose acylate film FUJIFILM CORPORATION (JP) 2011-10-27 US disclosed
US-20110262661-A1 Optical performance humidity dependency improving agent for cellulose acylate film FUJIFILM CORPORATION (JP) 2011-10-27 US disclosed
US-20110255037-A1 Cellulose acylate film, its production method, polarizer and liquid crystal display device FUJIFILM CORPORATION (JP) 2011-10-20 US disclosed
US-20110255037-A1 Cellulose acylate film, its production method, polarizer and liquid crystal display device FUJIFILM CORPORATION (JP) 2011-10-20 US disclosed
US-20110076423-A1 CELLULOSE ACYLATE FILM, RETARDATION FILM, POLARIZER AND LIQUID CRYSTAL DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2011-03-31 US disclosed
US-20110076423-A1 CELLULOSE ACYLATE FILM, RETARDATION FILM, POLARIZER AND LIQUID CRYSTAL DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 NUDT1 998/4885APP 604/4885MAPK1 4547/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 NUDT1 998/4885APP 604/4885MAPK1 4547/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 NUDT1 998/4885APP 604/4885MAPK1 4547/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 NUDT1 998/4885APP 604/4885MAPK1 4547/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 NUDT1 998/4885APP 604/4885MAPK1 4547/4885
US-20110262661-A1 Optical performance humidity dependency improving agent for cellulose acylate film ALKBH1, ACOT7, ALKBH2 NUDT1 476/4885APP 2292/4885MAPK1 3676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.